| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
GliptinDiabetes mellitus T2DM (Type2)| 1 | 2007 | Gliptins: a new class of oral hypoglycaemic agent. | 
| + | - | nl | QJM 100(11):671-7 (2007) |
| 2 | 2009 | Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. |
| + | - | nl | Cleve Clin J Med 76 Suppl 5(-):S28-38 (2009) |
| 3 | 2008 | What role will 'gliptins' play in glycemic control? |
| + | - | nl | Cleve Clin J Med 75(4):305-10 (2008) |
| 4 | 2010 | Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. |
| + | - | nl | Mayo Clin Proc 85(12 Suppl):S27-37 (2010) |
| 5 | 2010 | Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. |
| + | - | nl | Mayo Clin Proc 85(12 Suppl):S38-49 (2010) |
| 6 | 2010 | A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. |
| + | - | nl | Mayo Clin Proc 85(12 Suppl):S5-S14 (2010) |
| 7 | 2010 | The evolving place of incretin-based therapies in type 2 diabetes. |
| + | - | nl | Pediatr Nephrol 25(7):1207-17 (2010) |
| 8 | 2008 | Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. |
| + | - | nl | Medscape J Med 10(7):171 (2008) |
| 9 | 2008 | Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. |
| + | - | nl | Endocr Rev 29(3):367-79 (2008) |
